Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

TET1-Mediated Hypomethylation Activates Oncogenic Signaling in Triple-Negative Breast Cancer.

Good CR, Panjarian S, Kelly AD, Madzo J, Patel B, Jelinek J, Issa JJ.

Cancer Res. 2018 Aug 1;78(15):4126-4137. doi: 10.1158/0008-5472.CAN-17-2082. Epub 2018 Jun 11.

PMID:
29891505
2.

Nerve Injury-Induced Chronic Pain Is Associated with Persistent DNA Methylation Reprogramming in Dorsal Root Ganglion.

Garriga J, Laumet G, Chen SR, Zhang Y, Madzo J, Issa JJ, Pan HL, Jelinek J.

J Neurosci. 2018 Jul 4;38(27):6090-6101. doi: 10.1523/JNEUROSCI.2616-17.2018. Epub 2018 Jun 6.

PMID:
29875269
3.

Demethylator phenotypes in acute myeloid leukemia.

Kelly AD, Madzo J, Madireddi P, Kropf P, Good CR, Jelinek J, Issa JJ.

Leukemia. 2018 Mar 7. doi: 10.1038/s41375-018-0084-2. [Epub ahead of print]

PMID:
29556023
4.

Digital Restriction Enzyme Analysis of Methylation (DREAM).

Jelinek J, Lee JT, Cesaroni M, Madzo J, Liang S, Lu Y, Issa JJ.

Methods Mol Biol. 2018;1708:247-265. doi: 10.1007/978-1-4939-7481-8_13.

PMID:
29224148
5.

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.

Roboz GJ, Kantarjian HM, Yee KWL, Kropf PL, O'Connell CL, Griffiths EA, Stock W, Daver NG, Jabbour E, Ritchie EK, Walsh KJ, Rizzieri D, Lunin SD, Curio T, Chung W, Hao Y, Lowder JN, Azab M, Issa JJ.

Cancer. 2018 Jan 15;124(2):325-334. doi: 10.1002/cncr.31138. Epub 2017 Dec 6.

6.

Epigenetics and Precision Oncology.

Werner RJ, Kelly AD, Issa JJ.

Cancer J. 2017 Sep/Oct;23(5):262-269. doi: 10.1097/PPO.0000000000000281. Review.

PMID:
28926426
7.

Introduction: Cancer as an Epigenetic Disease.

Issa JJ.

Cancer J. 2017 Sep/Oct;23(5):255-256. doi: 10.1097/PPO.0000000000000285. No abstract available.

PMID:
28926424
8.

Caloric restriction delays age-related methylation drift.

Maegawa S, Lu Y, Tahara T, Lee JT, Madzo J, Liang S, Jelinek J, Colman RJ, Issa JJ.

Nat Commun. 2017 Sep 14;8(1):539. doi: 10.1038/s41467-017-00607-3.

9.

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.

Kantarjian HM, Roboz GJ, Kropf PL, Yee KWL, O'Connell CL, Tibes R, Walsh KJ, Podoltsev NA, Griffiths EA, Jabbour E, Garcia-Manero G, Rizzieri D, Stock W, Savona MR, Rosenblat TL, Berdeja JG, Ravandi F, Rock EP, Hao Y, Azab M, Issa JJ.

Lancet Oncol. 2017 Oct;18(10):1317-1326. doi: 10.1016/S1470-2045(17)30576-4. Epub 2017 Aug 24.

PMID:
28844816
10.

A novel isoform of TET1 that lacks a CXXC domain is overexpressed in cancer.

Good CR, Madzo J, Patel B, Maegawa S, Engel N, Jelinek J, Issa JJ.

Nucleic Acids Res. 2017 Aug 21;45(14):8269-8281. doi: 10.1093/nar/gkx435.

11.

The promise of epigenetic therapy: reprogramming the cancer epigenome.

Kelly AD, Issa JJ.

Curr Opin Genet Dev. 2017 Feb;42:68-77. doi: 10.1016/j.gde.2017.03.015. Epub 2017 Apr 14. Review.

PMID:
28412585
12.

DNA Hypomethylating Drugs in Cancer Therapy.

Sato T, Issa JJ, Kropf P.

Cold Spring Harb Perspect Med. 2017 May 1;7(5). pii: a026948. doi: 10.1101/cshperspect.a026948. Review.

PMID:
28159832
13.

Genetic Variants in Epigenetic Pathways and Risks of Multiple Cancers in the GAME-ON Consortium.

Toth R, Scherer D, Kelemen LE, Risch A, Hazra A, Balavarca Y, Issa JJ, Moreno V, Eeles RA, Ogino S, Wu X, Ye Y, Hung RJ, Goode EL, Ulrich CM; OCAC, CORECT, TRICL, ELLIPSE, DRIVE, and GAME-ON consortia.

Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):816-825. doi: 10.1158/1055-9965.EPI-16-0728. Epub 2017 Jan 23.

14.

Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.

Raynal NJ, Da Costa EM, Lee JT, Gharibyan V, Ahmed S, Zhang H, Sato T, Malouf GG, Issa JJ.

Mol Cancer Ther. 2017 Feb;16(2):397-407. doi: 10.1158/1535-7163.MCT-16-0588. Epub 2016 Dec 15.

15.

Transcriptional Selectivity of Epigenetic Therapy in Cancer.

Sato T, Cesaroni M, Chung W, Panjarian S, Tran A, Madzo J, Okamoto Y, Zhang H, Chen X, Jelinek J, Issa JJ.

Cancer Res. 2017 Jan 15;77(2):470-481. doi: 10.1158/0008-5472.CAN-16-0834. Epub 2016 Nov 22.

16.

Epigenetic synergy between decitabine and platinum derivatives.

Qin T, Si J, Raynal NJ, Wang X, Gharibyan V, Ahmed S, Hu X, Jin C, Lu Y, Shu J, Estecio MR, Jelinek J, Issa JJ.

Clin Epigenetics. 2015 Sep 11;7:97. doi: 10.1186/s13148-015-0131-z. eCollection 2015.

17.

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.

Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian H.

Lancet Oncol. 2015 Sep;16(9):1099-1110. doi: 10.1016/S1470-2045(15)00038-8. Epub 2015 Aug 19.

18.

Methylation of the estrogen receptor-alpha gene promoter is selectively increased in proliferating human aortic smooth muscle cells.

Ying AK, Hassanain HH, Roos CM, Smiraglia DJ, Issa JJ, Michler RE, Caligiuri M, Plass C, Goldschmidt-Clermont PJ.

Cardiovasc Res. 2000 Apr;46(1):172-9.

PMID:
10727665

Supplemental Content

Support Center